These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19450119)

  • 41. Therapeutic intent in the conduct of phase I antineoplastic drug trials.
    Markman M
    Oncology; 2009; 76(3):149-50. PubMed ID: 19169045
    [No Abstract]   [Full Text] [Related]  

  • 42. [Telemedicine and teledermatology (II): current state of research on dermatology teleconsultations].
    Romero G; Cortina P; Vera E
    Actas Dermosifiliogr; 2008 Oct; 99(8):586-97. PubMed ID: 19080890
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacoeconomic studies in Italy: a critical review of the literature.
    Cornago D; Li Bassi L; De Compadri P; Garattini L
    Eur J Health Econ; 2007 Jun; 8(2):89-95. PubMed ID: 17186206
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials.
    Tartari F; Conti A; Cerqueti R
    PLoS One; 2017; 12(8):e0183639. PubMed ID: 28829823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New therapies for GI cancers fall short.
    Hampton T
    JAMA; 2009 Jul; 302(4):373-4. PubMed ID: 19622809
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical and non-clinical factors influencing postoperative health-related quality of life in patients with colorectal cancer (Br J Surg 2008; 95: 1408-1415).
    Lee LH
    Br J Surg; 2009 Feb; 96(2):221; author reply 221-2. PubMed ID: 19160356
    [No Abstract]   [Full Text] [Related]  

  • 47. Comments on Costs of treating advanced colorectal cancer, Ross et al., Eur J Cancer 1996, 32A, S13-S17.
    Benson R; Wilson C; Williams MV
    Eur J Cancer; 1998 Mar; 34(4):593-4. PubMed ID: 9713318
    [No Abstract]   [Full Text] [Related]  

  • 48. Colorectal cancer treatment costs vary widely.
    Lang L
    Gastroenterology; 2009 Jan; 136(1):6-7. PubMed ID: 19059252
    [No Abstract]   [Full Text] [Related]  

  • 49. Critical review and appraisal of published clinical literature: useful skill in biotechnology product development.
    Foote M
    Biotechnol Annu Rev; 2008; 14():403-10. PubMed ID: 18606371
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Hematology: experiences with common national reports on new anti-cancer drugs].
    Kristensen JS; Bukh A
    Ugeskr Laeger; 2009 Mar; 171(13):1089. PubMed ID: 19321084
    [No Abstract]   [Full Text] [Related]  

  • 51. The colorectal cancer drug market.
    Ramos García L; Webster RM
    Nat Rev Drug Discov; 2024 Jun; 23(6):414-415. PubMed ID: 38336887
    [No Abstract]   [Full Text] [Related]  

  • 52. A year in review in Minerva Anestesiologica, 2008. I Critical Care. Experimental and clinical studies.
    Chiumello D; Caironi P; Colombo R; Grasso S; Gattinoni L
    Minerva Anestesiol; 2009; 75(1-2):47-57. PubMed ID: 19172145
    [No Abstract]   [Full Text] [Related]  

  • 53. Panel 1: methodological issues in pharmacoeconomic evaluations--clinical studies.
    Healey M; Deverka P
    Value Health; 1999; 2(2):73-7. PubMed ID: 16674336
    [No Abstract]   [Full Text] [Related]  

  • 54. Panel 3: methodological issues in conducting pharmacoeconomic evaluations--retrospective and claims database studies.
    Arnold RG; Kotsanos JG
    Value Health; 1999; 2(2):82-7. PubMed ID: 16674338
    [No Abstract]   [Full Text] [Related]  

  • 55. Panel 2: methodological issues in conducting pharmacoeconomic evaluations--modeling studies.
    Hay J; Jackson J
    Value Health; 1999; 2(2):78-81. PubMed ID: 16674337
    [No Abstract]   [Full Text] [Related]  

  • 56. Response to eczema and cancer risk: a critical appraisal and review of the literature.
    Hwang CY; Chen YJ; Liu HN; Chang YT
    Br J Dermatol; 2011 Sep; 165(3):462-3. PubMed ID: 21884042
    [No Abstract]   [Full Text] [Related]  

  • 57. Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?
    Garattini L; Padula A
    J R Soc Med; 2017 Mar; 110(3):98-103. PubMed ID: 28116955
    [No Abstract]   [Full Text] [Related]  

  • 58. Methodological reviews of economic evaluations in health care: what do they target?
    Hutter MF; Rodríguez-Ibeas R; Antonanzas F
    Eur J Health Econ; 2014 Nov; 15(8):829-40. PubMed ID: 23974963
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A critical review of the full economic evaluations of pharmacological treatments for colorectal cancer.
    Garattini L; Compadri PD; Koleva D; Pasina L; Nobili A
    J Med Econ; 2008; 11(1):177-97. PubMed ID: 19450119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A critical review of the full economic evaluations of pharmacological treatments for glaucoma.
    Koleva D; De Compadri P; Virgili G; Nobili A; Garattini L
    J Med Econ; 2008; 11(4):719-41. PubMed ID: 19450078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.